GGrantIndex
Sort

21,453 grants matching tuberculosis

Population Based Molecular Epidemiology of TB

$1,162,560
University Of California San Francisco · R01 · FY2004 · AI

Biocontainment Suite Renovation to Enhance Research

$1,162,443
Univ Of Massachusetts Med Sch Worcester · C06 · FY2005 · RR

Oral BCG: Optimizing mucosal vaccination against tuberculosis

$1,162,224
Philana Ling Lin · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · AI

PS05-003 TUBERCULOSIS CONTROL PROGRAM AND AIDS

$1,162,145
Shea S Rabley · South Carolina Department Of Public Health · U52 · FY2007 · PS

Production of Pedigreed SPF Rhesus Macaques

$1,162,130
Jeffrey A Roberts · University Of California At Davis · U42 · FY2021 · OD

A STINGing vaccine for TB

$1,161,477
William Ramses Bishai · Johns Hopkins University · R01 · FY2023 · AI

Development and Support of the Pathway Tools Software

$1,161,153
Peter D Karp · Sri International · R01 · FY2023 · AI

Development and Support of the Pathway Tools Software

$1,161,153
Peter D Karp · Sri International · R01 · FY2024 · AI

Sample Processing Cartridges for Rapid PCR TB Detection

$1,160,774
David Alland · Cepheid · R42 · FY2008 · AI

NATURAL HISTORY OF HIV INFECTION IN INJECTION DRUG USERS

$1,160,398
Johns Hopkins University · R37 · FY2000 · DA

CAPRISA Clinical Trials Unit for AIDS/Tuberculosis Prevention and Treatment

$1,160,092
Quarraisha Abdool Karim · Centre/Aids Programme/Res/South Africa · UM1 · FY2015 · AI

Addressing COVID-19 Testing Disparities in Vulnerable Populations Using a Community JITAI (Just in Time Adaptive Intervention) Approach - Phase II

$1,158,954
David D McPherson · University Of Texas Hlth Sci Ctr Houston · UL1 · FY2022 · TR

Tuberculosis Surveillance, Prevention and Control, and Laboratory Upgrade

$1,158,894
Maureen E Murphy · Ohio State Department Of Health · U52 · FY2012 · PS

Optimization and Advanced Proof-of-Concept Studies of a Listeria-vectored Multi-Antigenic Vaccine against Tuberculosis

$1,158,564
Marcus Aaron Horwitz · University Of California Los Angeles · R01 · FY2020 · AI

DRAMATIC Phase 2 Duration Randomized MDR-TB Treatment Trial

$1,157,460
Payam Nahid · University Of California, San Francisco · U01 · FY2025 · AI

New targets against tuberculosis

$1,156,431
Deborah T Hung · Broad Institute, Inc. · R01 · FY2018 · AI

A dual function TB subunit vaccine designed for non-interference with BCG and post-exposure activity

$1,155,591
Rasmus Skaarup Mortensen · Statens Serum Institute · R01 · FY2021 · AI

Stellenbosch University Clinical Trials Unit (SUN-CTU)

$1,155,500
Mark Fredric Cotton · Stellenbosch University · UM1 · FY2015 · AI

DEVELOPMENT OF A RECOMBINANT LISTERIA MONOCYTOGENES BOOSTER VACCINE AGAINST TUBERCULOSIS

$1,155,000
University Of California, Los Angeles · · FY2012 · Department of Defense

TB Surrogate Markers for Assessing Reponse to Treatment (TB SMART Study)

$1,154,896
Payam Nahid · University Of California, San Francisco · R01 · FY2015 · AI

ALABAMA/ZAMBIA HIV VACCINE CLINICAL TRIALS UNIT (HVTU)

$1,154,810
University Of Alabama At Birmingham · U01 · FY2000 · AI

Durban International Clinical Trials Unit

$1,154,244
Umesh G Lalloo · University Of Kwazulu-Natal · UM1 · FY2012 · AI

International Research in Korea: Clinical Studies of Drug-Resistant Tuberculosis

$1,153,780
Clifton Barry · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI

Production of Pedigreed SPF Rhesus Macaques

$1,153,561
Jeffrey A Roberts · University Of California At Davis · U42 · FY2022 · OD

Optimization and preclinical development of a TB Multiple Antigen Presenting System (MAPS) vaccine

$1,153,542
Richard Malley · Boston Children'S Hospital · R01 · FY2021 · AI